Summary
DYF1 Chart
Why Dynavax Stock Soared Today
Sanofi is launching an all-cash tender offer for Dynavax's shares. The French pharma giant's bid comes at a sizable premium to Dynavax's recent closing price.
Dynavax Technologies Stock Soars on Buyout Buzz
Biotech stock Dynavax Technologies Corp (NASDAQ:DVAX) is soaring today, last seen up 38.7% at $15.43, after reports that Sanofi (SNY) plans to acquire the company in an all-cash deal worth roughly $2.2 billion.
Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying
Shares of Dynavax Technologies (DVAX) skyrocketed after French drugmaker Sanofi (SNY) said it would buy the biopharmaceutical firm for $2.2 billion to expand its Hepatitis B offerings and enter the shingles vaccine market.
Dynavax Technologies Corporation (DYF1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Dynavax Technologies Corporation ever had a stock split?
Dynavax Technologies Corporation Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Ryan Spencer CEO | XDUS Exchange | US2681582019 ISIN |
| US Country | 405 Employees | - Last Dividend | 10 Nov 2014 Last Split | 19 Feb 2004 IPO Date |
Overview
Dynavax Technologies Corporation is a commercial stage biopharmaceutical company with a strong focus on the development and commercialization of vaccines within the United States. Established initially as Double Helix Corporation and rebranded to its current name in September 1996, Dynavax has positioned itself prominently in the field of infectious diseases, particularly hepatitis B. Headquartered in Emeryville, California, the company boasts a robust collaboration network, engaging with various international pharmaceutical entities such as Valneva Scotland Limited, Zhejiang Clover Biopharmaceuticals, Inc., Clover Biopharmaceuticals (Hong Kong) Co., Limited, Biological E. Limited, PT Bio Farma, Medigen Vaccine Biologics, and Serum Institute of India Pvt. Ltd. This extensive partnership framework underlines Dynavax's commitment to leveraging shared expertise for advancing its vaccine development and commercialization agenda.
Products and Services
- HEPLISAV-B
Dynavax's flagship product, HEPLISAV-B, represents a significant advancement in the prevention of hepatitis B virus infection. Approved for use in individuals 18 years of age and older, this vaccine distinguishes itself by offering protection against all known subtypes of the hepatitis B virus. HEPLISAV-B's market presence extends beyond the United States, reaching into European territories, thus affirming Dynavax's international operational footprint. The innovative incorporation of CpG 1018, a proprietary adjuvant, in HEPLISAV-B, not only enhances the vaccine's efficacy but also underscores Dynavax's capability in novel adjuvant formulation.
- CpG 1018 Adjuvant
Another pivotal product in Dynavax's portfolio is the CpG 1018 adjuvant, a critical ingredient that boosts the immune response to HEPLISAV-B. The adjuvant's effectiveness has propelled its utility beyond the confines of Dynavax's proprietary vaccine, making it a sought-after component in the formulation of various other vaccines globally. The manufacturing and sale of CpG 1018 adjuvant represent key business areas for Dynavax, facilitating broad-based collaborations and partnerships within the biopharmaceutical industry. This contributes significantly to the company's revenue streams while advancing the global vaccine development efforts.
